The Evaluation of Hepatitis B Seroprevalence in Children Applied to a State Hospital in Ankara

Hüsniye Altan, Saadet Demirtaş, Demet Taş, Işıl İrem Budakoğlu
2.382 331

Abstract


Objectives: The aim of this study is to investigate the seroprevalence of HBsAg and frequency of anti-HBs positivity in 0- 18 years old children in Ankara province.

Material and Methods: Retrospectively, 4210 boys and 2983 girls between 0-18 years who applied to Ankara Gazi Mustafa Kemal State Hospital between January 2009 and June 2014 and were examined for HBsAg and anti- HBs levels by using Micro ELİSA technics were included. Children were categorized into five age groups. 

Results: 4231 HBsAg levels were measured and HBsAg positivity was found to be 0.80% (34/4231).  64.70% (22/34) of these were male, 35.30%; (12/34) were female. There was no significant relationship between the two groups regarding HBsAg positivity (p=0,389). 2962 anti-HBs levels were measured and   anti-HBs seropositivity was found as 75.30% (2231/2962); anti-HBS seropositivity were 73.40%; (1173/1599) for males and 77,60%; (1057/1363) for females. There was significant relationship between two groups regarding antiHBs seropositivity (p=0,011). According to the age groups, seropositivity ratios were found as 78.70% (118/150), 60.60% (260/429), 64.20% (312/486), 85.10% (798/938) and 77.40% (743/960) in  first, second, third, fourth and fifth groups respectively; and statistically significant relationship was found between them.

Conclusion: Our study is important for evaluating the seroepidemiology of hepatitis B vaccination that has been administered for 16 years and before. It may also be useful for similar studies comparing different regions.


Keywords


Hepatitis B, seroepidemiology, hepatitis B vaccination

Full Text:

PDF (Türkçe)


References


Daniels D, Grytdal S, Wasley A. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009;58:1–27.

Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39–46.

Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068–71.

Andrade AF, Oliveira-Silva M, Silva SG, Motta IJ, Bonvicino CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem Inst Oswaldo Cruz 2006;101:673–6.

Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329–39.

Banatvala J, Van Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000;19:877–85.

Noyan N, Aycan S, Ülkemizde rutin aşılama programları ve uygulamada karşılaşılan sorunlar. Klinik Çocuk forumu Pediatrik Aşılar Özel Sayısı 2002;2(2):1-8.

Assad S, Francis A. Over a decade of experience with a yeast recombinant hepaatitis B vaccine. Vaccine 1999;18:57-67.

Venters C, Graham W,Cassidy W. Recombiwax-hb:perspectives past, present and future Expert Rev vaccines 2004;3:119-29.

European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–5.

Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. ClinInfect Dis. 2011;53:68–75.

Tatlı MM, Aslan G, Ataş A, Kösecik M. Bebeklerin rutin aşılamasında kullanılan ve yalnız S antijeni içeren hepatit B aşısının immunojenitesinin ve tolerabilitesinin S+preS2 anti¬jeni içeren bir aşı ile karşılaştırmalı değerlendirilmesi. Çocuk Sağlığı ve Hastalıkları Dergisi 2001;44:109-14.

Nalbantoğlu B, Nalbantoğlu A, Külcü NU, Say A. Dokuz Ay - 8 Yaş Arası Çocuklarda Hepatit B Seroprevalansı ve Aşılanma Durumları. Çocuk Dergisi. 2010;10(3):116-21.

Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L. The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination JID 2010:202(2):192-201.

Süleyman A, Gökçay G, Badur S, Aykın S, Kılıcı G, Tamay Z. Süt Çocukluğunda Hepatit B Aşısı Uygulanan Çocuklarda Serolojik Durumun Değerlendirilmesi Mikrobiyol Bul 2012;46(1):47-56.

Tosun SY, Eser E, Sır E, Bayındırlı D, İrencin D, Obalı C. Manisa ili Muradiye Sağlık Ocağı merkez bölgesinde 1998 yılında hepatit B aşılama programına alınan cocuklarda dört yıl sonraki aşı koruyuculuk düzeyinin araştırılması. MN Klinik Bilimler&Doktor 2003;9(4):459-66.

Erol M, Velipaşaoğlu S, Uğuz A,Artan R,Yeğin O. Türk Bebeklerinde Hepatit B aşısının Etkinliği. Türk Pediatri Arşivi 2000;35(4):252-5.

Mast EE, Ward JW. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia; PA: Saunders; 2008.

McMahon BJ, Dentinger CM, Bruden D, et al. Antibody level and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390–6.

Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations frombirth. Pediatr Infect Dis J 2004;23:650–5.

Ayvaz A, Nur N, Engin A, Çetinkaya S. Sivas il merkezinde yaşayan ilkokul birinci sınıf öğrencisi çocuklarda hepatit B ve hepatit C yaygınlığı. Türk Ped Arşiv 2010:45:132-6.

Kaya A, Erbey MF, Okur M, Sal E, Üstyol L, Bektaş MS. Van Yöresinde 0-18 Yaşları Arasındaki Çocuklarda Hepatit B Seropozitifliği ve Aşılanma Durumu. J Pediatr Inf 2011;5:132.

TC. Saglık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü Genişletilmiş Bağışıklama Programı Genelgesi (Daimi Genelge) 30.11.2006 tarih 18607– 2006/120, www.saglik.gov.tr/Eklenti/1117,gbpgenelge2008pdf.pdf?0, Erişim tarihi: 10.09.2016.

Schönberger K, Riedel C, Rückinger S, Mansmann U, Jilg W, Kries RV. Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy: A Meta-analysis.In: Pediatr Infect Dis J 2013 ;32(4):307-13.

Demirören K, Deveci U, DemirörenS. Sağlık Bakanlığımızın Uyguladığı Hepatit B aşılarının Sağladığı Anti-HBs Değerleri 2007;21(5):183-5.

Jan CF, Huang KC, Chien YC, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010;51:1547–54.

Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561–5.

Sağlık Bakanlığı [İnternet]. http://www.sb.gov.tr/TR/dosya/2014/ek1. T.C. Sağlık Bakanlığı Sağlık İstatistikleri Yıllığı 2013 xlsx (Erişim Tarihi 15.10.2014).






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.